Post hoc analysis of 281 adults with acute schizophrenia entering a 52-week open-label olanzapine/samidorphan extension: PANSS Marder Negative Factor score fell by an LS mean of 8.2 points at week 56, and by 9.6 in those with prominent negative symptoms.
Secondary analysisn = 281
McIntyre et al. The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia